Best-of des articles de synthèse
The human antibody response to influenza A virus infection and vaccination.
Krammer F.
Nat Rev Immunol. 2019 Mar 5. doi: 10.1038/s41577-019-0143-6.
Antibody responses to viral infections: a structural perspective across three different enveloped viruses.
Murin CD, Wilson IA, Ward AB.
Nat Microbiol. 2019 May;4(5):734-747. doi: 10.1038/s41564-019-0392-y.
Advances in respiratory virus therapeutics - A meeting report from the 6th ISIRV Antiviral Group conference.
Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC.
Antiviral Res. 2019 Apr 8;167:45-67. doi:10.1016/j.antiviral.2019.04.006.
Baloxavir marboxil: the new influenza drug on the market.
O'Hanlon R, Shaw ML. Curr Opin Virol. 2019 Mar 7;35:14-18. doi: 10.1016/j.coviro.2019.01.006.
The intersection of sex and gender in the treatment of influenza.
Morgan R, Klein SL.
Curr Opin Virol. 2019 Mar 19;35:35-41. doi:10.1016/j.coviro.2019.02.009.
Mechanisms of Bacterial Superinfection Post-influenza: A Role for Unconventional T Cells.
Paget C, Trottein F.
Front Immunol. 2019 Mar 1;10:336. doi:10.3389/fimmu.2019.00336.
Interplay between Influenza Virus and the Host RNA Polymerase II Transcriptional Machinery.
Walker AP, Fodor E.
Trends Microbiol. 2019 May;27(5):398-407. doi: 10.1016/j.tim.2018.12.013.
Communiqué issu des dernières rencontres de l'ESCMID qui rappelle l'importance et l'enjeu des sujets grippes non-symptomatiques.